starting in August 2025. Focused on the Eastern region of Afghanistan, the campaign will deploy Tropis ID to administer 1.3 million fractional doses of inactivated polio vaccine (fIPV) to children ages 5 and under in parallel to oral polio vaccine...
Toddler Development - Third Edition (Bayley-III), as well as safety data over a five-year period from clinical studies 201, 202, and 401. Data from treated patients (n=22) in the studies 201, 202, and 401 was compared with data from untreated...
the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR...
for treating their own patient’s pain and fever over the ingredient profiles in Tylenol®'s top-selling comparable products1. “This should be a wake-up call for the industry,” said David Johnson, CEO and Co-Founder of Genexa. “Pediatricians are...
the same active ingredient, far exceeding the approximately 30 percent achieved by existing patches. It also showed around 160 times higher bioavailability than semaglutide oral tablet. Therapeutic plasma levels were maintained for one week,...
dosing of the first patient in its Phase 2b trial, FORTIFY, evaluating orticumab in patients with a history of type 1 myocardial infarction (MI) and confirmed elevated coronary inflammation. The Company is developing orticumab for secondary...
of Venofer® Injection, is expected to be available imminently in single dose vials in the following strengths: 50 mg/2.5mL, 100mg/5mL and 200mg/10mL. Viatris Chief R&D Officer Philippe Martin said, "The first FDA approval of a generic iron sucrose...
in gene and cell therapy, announced the launch of its cGMP Adeno-Associated Virus (AAV) manufacturing services at its 128,000 sq. ft. state-of-the-art facility in Hopewell, New Jersey. This strategic expansion is designed to meet growing industry...
(FDA) has granted accelerated approval for Modeyso™ (dordaviprone) for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior...
Roche announced the U.S. Food and Drug Administration (FDA) 510(k) clearance for the cobas® Respiratory 4-flex. This is the first FDA-cleared assay utilizing Roche's innovative TAGS (Temperature-Activated Generation of Signal) technology, designed...
significantly by vessel size, organ involvement, and clinical symptoms, making timely and accurate diagnosis challenging.1-7 MosaiQ AiPlex® VAS multiplex assay: Fast, Easy, Comprehensive The MosaiQ AiPlex VAS assay enables simplified serological...
SkinCeuticals, the #1 Medical Aesthetic Skincare Brand Worldwide*, announces the launch of A.G.E. Interrupter Ultra Serum, the latest science-backed product in its A.G.E. line. Sagging skin is a top concern driving patients to dermatologists, and...
and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North...
for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the...
is made of 52% ISCC Plus certified bio-based feedstock. The bottle is produced using a mass balance approach equivalent to 100% bio-based content. Together, the pump and bottle components result in an overall circular material content of 60% for...
bioanalysis company reinventing the speed and scalability of drug development, announced it has raised an additional $11 million in funding, bringing its total raised to $17.5 million. The new financing was led by The Aligned Fund, with...
BD-conducted pre-clinical and clinical studies, including a device clinical study demonstrating excellent performance with 100% of study participants stating they would likely use the BD Libertas™ Wearable Injector if prescribedi,ii. The...
higher efficacy and purity compared to the current state-of-the-art AAV manufacturing processes. We are talking about KLTO-101 for Alzheimer's and Parkinson's diseases, KLTO-202 for ALS and other motor neuron diseases, and KLTO-303 for treatment of...
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced the launch of Dehydrated Alcohol Injection, USP in the United States as a therapeutic generic equivalent of Ablysinol®, which ended its...
provides the same efficacy and safety, and is a generic equivalent to the reference product, Torbugesic®. Available in 10 mg/mL concentrations in 20 mL and 50 mL multi-dose vials, our unique 20 mL vial offers veterinarians more flexible dosing...